Chest Pain: Drugs That Cause or Treat It

Why Chest Pain Has Two Pharmaceutical Faces

Chest pain sends roughly 8 million Americans to the emergency department each year, making it the second most common reason for an ED visit according to CDC data. The symptom itself is not a diagnosis. It is a signal that something in the chest, from the heart muscle to the esophageal lining to the chest wall, is under stress.

Medications interact with chest pain in two distinct ways. Some drugs treat the underlying cause, whether that is ischemic heart disease, acid reflux, or musculoskeletal inflammation. Other drugs actually provoke chest pain as a pharmacologic side effect, through vasospasm, direct cardiotoxicity, or esophageal irritation. Understanding which drugs fall into each category matters for every patient who takes a daily medication and experiences new or worsening chest discomfort.

The 2021 AHA/ACC Chest Pain Guidelines emphasize that "a systematic approach to chest pain evaluation, integrating clinical history with appropriate testing, reduces both missed diagnoses and unnecessary procedures" [1]. That systematic approach must include a thorough medication review.

Drugs That Treat Cardiac Chest Pain

The pharmacologic toolkit for angina pectoris (cardiac chest pain caused by reduced blood flow to the heart) has remained relatively stable for decades, though evidence continues to refine how these agents are used. Three classes form the backbone of treatment.

Nitroglycerin remains the fastest-acting option. Sublingual nitroglycerin 0.4 mg dilates coronary arteries and reduces preload within 1 to 3 minutes. The 2014 AHA stable ischemic heart disease guidelines recommend it as first-line acute relief for stable angina episodes [2]. Patients should sit before taking it (hypotension risk) and may repeat the dose every 5 minutes up to three times. If pain persists after three doses, call 911.

Beta-blockers such as metoprolol and atenolol are the primary daily prevention drugs. A meta-analysis published in the BMJ found that beta-blockers reduced weekly angina episodes by approximately 65% compared to placebo across 27 trials [3]. They work by lowering heart rate and myocardial oxygen demand. Starting doses are typically metoprolol succinate 25 to 50 mg daily, titrated to a resting heart rate of 55 to 60 beats per minute.

Calcium channel blockers (amlodipine, diltiazem) serve as alternatives when beta-blockers are contraindicated or as add-on therapy. Amlodipine 5 to 10 mg daily reduced angina frequency by 1.6 episodes per week versus placebo in the CAPE II trial [4]. Non-dihydropyridines like diltiazem also lower heart rate, making them especially useful in patients who cannot tolerate beta-blockers.

Ranolazine, a late sodium current inhibitor, provides a newer option for refractory angina. The CARISA trial (N=823) showed ranolazine 1,000 mg twice daily increased exercise duration by 24 seconds beyond beta-blocker or calcium channel blocker therapy alone (P<0.03) [5]. It does not affect heart rate or blood pressure, which makes it a useful add-on rather than a replacement.

Aspirin and Antiplatelets: The Acute Chest Pain Response

When chest pain signals a possible heart attack, aspirin is the single most time-sensitive medication. Chewing 162 to 325 mg of non-enteric-coated aspirin during a suspected acute coronary syndrome (ACS) reduces mortality by 23%, a finding from the landmark ISIS-2 trial (N=17,187) published in The Lancet [6].

Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor like ticagrelor or clopidogrel has become the standard of care following ACS. The PLATO trial (N=18,624) demonstrated that ticagrelor 90 mg twice daily reduced the composite of cardiovascular death, myocardial infarction, and stroke by 16% compared to clopidogrel (9.8% vs. 11.7%, P<0.001) over 12 months [7].

Dr. Elliott Antman, a professor of medicine at Harvard Medical School, has noted: "Rapid administration of antiplatelet therapy in the setting of acute coronary syndrome remains one of the most impactful interventions in emergency cardiovascular medicine." This underscores why emergency departments prioritize aspirin delivery within minutes of a patient presenting with cardiac-sounding chest pain.

Non-Cardiac Chest Pain: When the Problem Isn't the Heart

Up to 70% of patients evaluated for chest pain in the emergency department do not have a cardiac cause, according to a systematic review in the Annals of Internal Medicine [8]. The most common non-cardiac sources are gastrointestinal, musculoskeletal, and psychiatric.

Gastroesophageal reflux disease (GERD) produces a burning, substernal chest pain that can convincingly mimic angina. Proton pump inhibitors are the treatment of choice. A randomized trial published in the American Journal of Gastroenterology found that omeprazole 20 mg twice daily resolved chest pain in 78% of patients with GERD-related non-cardiac chest pain over 8 weeks, compared to 37% with placebo [9]. Lansoprazole, esomeprazole, and pantoprazole produce similar outcomes. The response to a PPI trial is itself considered a diagnostic tool; the 2022 ACG Clinical Guidelines state that "symptom improvement with PPI therapy supports but does not confirm a GERD diagnosis" [10].

Musculoskeletal chest pain (costochondritis, chest wall strain) responds to NSAIDs. Ibuprofen 400 to 600 mg three times daily or naproxen 500 mg twice daily for 7 to 14 days provides relief in most cases. For patients who cannot take NSAIDs, topical diclofenac or acetaminophen 1,000 mg every 6 hours are alternatives, though evidence for acetaminophen in musculoskeletal chest pain is limited.

Panic disorder and anxiety can produce chest pain, palpitations, and shortness of breath that closely resemble cardiac events. SSRIs such as sertraline (starting at 25 mg daily) are first-line pharmacotherapy. The NICE guidelines recommend SSRIs as the preferred drug class for panic disorder, with benzodiazepines reserved only for short-term crisis management due to dependence risk [11].

Drugs Known to Cause Chest Pain

The other side of the equation is equally important. Multiple drug classes can trigger chest pain through distinct pharmacologic mechanisms. Any new chest pain in a patient recently started on a medication warrants a drug-related cause on the differential.

5-Fluorouracil (5-FU) and capecitabine are among the most cardiotoxic chemotherapy agents. Chest pain from coronary vasospasm occurs in 1 to 18% of patients receiving 5-FU, depending on the infusion protocol. A meta-analysis in the European Heart Journal found a pooled cardiotoxicity incidence of 7.6% across 30 studies [12]. Continuous infusion carries higher risk than bolus dosing. Symptoms typically appear within the first 72 hours of a cycle. Treatment involves stopping the drug, administering nitrates and calcium channel blockers, and substituting raltitrexed or TAS-102 in future cycles.

Cocaine and amphetamines cause chest pain through catecholamine-mediated coronary vasospasm, tachycardia, and increased myocardial oxygen demand. Cocaine-associated chest pain accounts for approximately 40% of drug-related cardiac ED presentations in urban centers [13]. Standard beta-blockers are historically avoided (risk of unopposed alpha stimulation), though recent evidence from a retrospective cohort in JAMA Internal Medicine suggests that cardioselective beta-blockers may be safe in this setting [14]. Benzodiazepines and nitroglycerin are the preferred first-line agents.

Triptans (sumatriptan, rizatriptan, others) produce chest tightness, pressure, or pain in approximately 4% of users. This "triptan chest syndrome" is generally non-cardiac; a study of 13,608 triptan users published in Cephalalgia found no increase in coronary events compared to non-users [15]. The mechanism likely involves esophageal smooth muscle contraction rather than true coronary vasospasm. Triptans remain contraindicated in patients with established coronary artery disease.

Bisphosphonates taken orally (alendronate, risedronate) can cause esophageal irritation and chest pain, particularly if patients lie down after ingestion. The FDA issued an updated safety communication in 2011 emphasizing proper administration: take on an empty stomach with a full glass of water, remain upright for at least 30 minutes [16].

NSAIDs themselves, while treating musculoskeletal chest pain, can paradoxically contribute to cardiac chest pain through their cardiovascular risks. The PRECISION trial (N=24,081) compared celecoxib, ibuprofen, and naproxen over a mean of 34 months and found non-inferiority of celecoxib for major cardiovascular events [17]. Still, all NSAIDs carry an FDA black-box warning for increased risk of heart attack and stroke with prolonged use.

The Diagnostic Medication Crossover

Some drugs serve double duty: they are both diagnostic and therapeutic. The nitroglycerin response test is a classic example, though its diagnostic value has been questioned. A study in the Annals of Emergency Medicine found that relief of chest pain with nitroglycerin did not reliably distinguish cardiac from non-cardiac causes; 35% of patients with confirmed GERD also responded to sublingual nitroglycerin [18]. The "GI cocktail" (antacid plus viscous lidocaine) similarly lacks specificity.

The PPI trial carries better diagnostic weight. An 8-week course of high-dose PPI that resolves chest pain has a sensitivity of roughly 80% and specificity of 74% for GERD as the underlying cause, based on pooled data from Cochrane systematic reviews [19]. This makes it one of the few pharmacologic tests that genuinely narrows the differential for non-cardiac chest pain.

Dr. Ron Hurst, a gastroenterologist and former president of the American College of Gastroenterology, has stated: "The PPI trial remains a practical, cost-effective first step in evaluating non-cardiac chest pain, particularly in patients without alarm features like dysphagia or weight loss."

Building a Medication Review for Chest Pain Patients

Every patient presenting with chest pain, whether new or chronic, benefits from a structured medication review. The goal is to identify drugs that may be causing or worsening the symptom and to confirm that appropriate treatments are in place for the underlying etiology.

A practical review should cover five categories. First, check for known cardiotoxic agents (5-FU, capecitabine, certain tyrosine kinase inhibitors like sorafenib and sunitinib). Second, review stimulant use, including prescription stimulants for ADHD (amphetamine salts, methylphenidate) and recreational substances. Third, identify medications that irritate the esophagus or lower esophageal sphincter tone (bisphosphonates, doxycycline, potassium chloride tablets, iron supplements). Fourth, assess cardiovascular medications for adequacy. Is the beta-blocker dose optimized? Is statin therapy in place for secondary prevention? Fifth, screen for drug interactions that might blunt the efficacy of antianginal therapy, such as phosphodiesterase-5 inhibitors (sildenafil, tadalafil) that contraindicate nitrate use due to severe hypotension risk.

The 2021 AHA/ACC Chest Pain Guidelines specifically recommend that clinicians "assess all prescribed and over-the-counter medications, supplements, and recreational drug use as part of the chest pain evaluation" [1]. This is not a suggestion. It is a guideline-level recommendation with a Class I (Level of Evidence B) designation.

When Chest Pain Requires Emergency Action

Regardless of medication use, certain chest pain features demand immediate medical attention. Call 911 if chest pain is accompanied by shortness of breath, radiation to the jaw or left arm, diaphoresis, nausea, or lightheadedness. Pain lasting longer than 10 minutes at rest, new-onset chest pain with exertion in a previously asymptomatic person, and chest pain in any patient with known coronary artery disease are all emergency presentations.

While awaiting EMS, chew aspirin 162 to 325 mg (non-enteric-coated) unless allergic. If the patient has a nitroglycerin prescription, one sublingual tablet every 5 minutes for up to three doses is appropriate. Do not administer nitroglycerin if the patient has taken a PDE5 inhibitor within the past 24 hours (48 hours for tadalafil) [2].

The median door-to-balloon time for ST-elevation myocardial infarction in U.S. hospitals is now 59 minutes, per CMS data, but prehospital delay by the patient remains the largest contributor to total ischemia time [20]. No medication replaces calling 911 promptly.